Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.
Day 3

SWISS AMI: Stem cells infusion after primary angioplasty

solaci
solaci
415
0

The trial enrolled 200 patients post AMI treated with successful PCI, with LVEF ≤45% randomized to placebo, to receive early (before 7 days) or late (after 7 days) stem cells infusion. Primary end point was LVEF at 4 months. At follow up, stem cells infusion, both early and late, did not improve LVEF, compared to placebo.

Conclusion: Stem cells infusion post PCI does not improve EF in patients with ventricular dysfunction. 

5_daniel_surder
Daniel Sürder
2012-11-06

Original title: Results of the Swiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (Swiss Ami) Trial

Previous article
TIME: Use and duration of bone marrow derived stem cells infusion for the treatment of post infarction ventricular dysfunction.
Next article
PILOT trial: Pilot study of two levels of hypothermia in comatose survivors after out-of-hospital cardiorespiratory arrest.
solaci
solaci

More articles by this author

PILOT trial: Pilot study of two levels of hypothermia in comatose survivors after out-of-hospital cardiorespiratory arrest.

solaci - 0
Hypothermia is neuroprotective, because it reduces brain oxygen consumption in 6%, suppresses chemical reactions associated to reperfusion, reduces free radicals and mitochondrial damage. It...

TIME: Use and duration of bone marrow derived stem cells infusion for the treatment of post infarction ventricular dysfunction.

solaci - 0
This study randomized 120 patients with acute myocardial infarction after successful primary angioplasty with a residual ejection fraction (LVEF) <45%. An intracoronary infusion with...

POSEIDON: Transendocardial infusion of autologous vs. allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy.

solaci - 0
Safety and efficacy of autologous vs. allogeneic mesenchymal stem cells had not yet been compared. This trial randomized 30 patients with LV dysfunction due...

SCIPIO trial: Intracoronary infusion of autologous cardiac stem cells improve ventricular function.

solaci - 0
This is the first trial that used autologous cardiac stem cells for the treatment of ischemic cardiomyopathy. It consecutively enrolled 37 patients with reduced...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 3

PILOT trial: Pilot study of two levels of hypothermia in comatose survivors after out-of-hospital cardiorespiratory arrest.

Hypothermia is neuroprotective, because it reduces brain oxygen consumption in 6%, suppresses chemical reactions associated to reperfusion, reduces free radicals...
solaci -
SOLACI Sessionsspot_img

Recent Articles

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Dr. Juan Manuel Pérez - 0
Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

Left Atrial Appendage Closure: Implantation Depth Could Determine Thrombosis Risk

Dr. Andrés Rodríguez - 0
Left atrial appendage closure (LAAC) has undergone significant advances over the past two decades. This progress has been driven by the development of new...

Influence of cusp-overlap and three-cusp coplanar techniques on new-onset conduction disturbances after TAVI

Dr. Juan Manuel Pérez - 0
New-onset conduction disturbances remain one of the most frequent complications after transcatheter aortic valve implantation (TAVI), being associated with worse long-term clinical outcomes. Among...